Issue link: https://www.e-digitaleditions.com/i/1208415
Recent news about companies that support development of orally inhaled and nasal drug products, including new indications for OINDPs and results of clinical studies. Inhalation February 2020 7 Industry news 3M to divest substantially all drug delivery business ST. PAUL, MINNESOTA and NEW YORK, NEW YORK—3M Company has announced it will sell substantially all of its drug delivery business to an affiliate of Altaris Capital Partners, LLC. 3M is global leader in drug delivery that partners with pharmaceutical and biotech companies to develop and manufac- ture pharmaceutical products using inhalation, transdermal, micronee- dle and conventional drug delivery technologies. 3M will retain its transdermal drug delivery compo- nents business and have a minority interest in the new business. Approx- imately 900 3M employees, who primarily support the business, are expected to join the new company. e transaction is projected to close in the first half of 2020. Koura will supply 152a MDI propellant to Chiesi RUNCORN, UNITED KING- DOM—Koura, previously known as Mexichem Fluor, has announced an agreement to supply the new, low-carbon-footprint medical pro- pellant Zephex ® 152a to Chiesi Farmaceutici for inhalation prod- uct development and clinical trials. Zephex 152a is a new, sustainable medical propellant that has been under development by Koura for several years for use in metered dose inhalers (MDIs) for treat- ment of respiratory disorders such as asthma and COPD. A Koura news release stated explained that "MDI products using Zephex 152a will bring about a greater than 90% reduction in inhaler carbon footprints compared to current MDIs and result in the environ- mental impact of MDIs being as low as other 'green' inhaler technol- ogies such as dry powder inhalers (DPIs)." Koura has invested in a new laboratory at their new medical division headquarters in Chester, United Kingdom. ey noted the facility will be the first in the world to offer dedicated pharmaceutical- grade laboratories specializing in Zephex 152a and will help facilitate the commercial development of 152a-based inhaled medicines. Recipharm offers to acquire Consort Medical STOCK HOLM, SW EDEN— Recipharm A B has announced plans to acquire Consort Medical, plc. Recipharm offers manufactur- ing services for pharmaceuticals in various dosage forms, production of clinical trial material and active pharmaceutical ingredients (APIs), and pharmaceutical product devel- opment. Consort is a global drug delivery and device company and integrated contract development and manufacturing organization (CDMO). Recipharm's holdings also include Bespak, a drug device developer and manufacturer, and Aesica, which focuses on API and finished dose manufacturing. e enlarged Recipharm Group will be positioned to become a top-five global CDMO, able to offer inte- grated device development and sup- ply, combined with commercial- scale finished dose manufacturing. continued on page 30